Response: NAD targeting efficiently kills hematologic cancer cells

2009 
Response We thank Cea and coauthors for sharing their results on APO866 activity in hematologic malignancies. We reported that primary cells and cell lines from patients with hematologic malignancies are highly sensitive toward APO866.[1][1] Results were obtained from MTT (thiazolyl blue
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    1
    References
    0
    Citations
    NaN
    KQI
    []